Novavax Scientific Leadership to Present RSV Maternal Immunization Program Phase 3 Data and Participate in Panel on COPD at World Vaccine Congress
Details are as follows:
|Oral Presentation Title:||Phase 3 and beyond: The RSV F nanoparticle vaccine for infants via maternal immunization|
|Date:||Tuesday, April 16|
|Time:||3:40 p.m. E.T.|
|Panel Title:||COPD: The interplay of virus, bacterial pathogens and exacerbation, an opportunity for vaccines?|
|Date:||Wednesday, April 17|
|Time:||11:30 a.m. E.T.|
|Moderator:||Tod Merkel, Ph.D., Professor of Laboratory for Respiratory and Special Pathogens Division, Center for Biologics Evaluation and Research, Food and Drug Administration|
|Panelists:||Louis Fries III, M.D., Senior Vice President, Chief Medical Officer, Novavax
Outi Vaarala, M.D., Ph.D., Senior Director, Respiratory Research, AstraZeneca
Sanjay Sethi, Professor And Chief, Pulmonary, Critical Care and Sleep Medicine; Assistant Vice President for Health Sciences, The University at Buffalo
ResVax is an RSV fusion (F) protein recombinant nanoparticle vaccine with aluminum phosphate as an adjuvant.
Senior Manager, Investor & Public Relations
Source: Novavax, Inc.